StockNews.AI
NKTR
StockNews.AI
19 days

Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

1. Nektar will announce Q2 financial results on August 7, 2025. 2. CEO Howard Robin will host a conference call post-results. 3. Nektar's lead product is under trials for autoimmune diseases. 4. NKTR-358 is in Phase 2b trials for atopic dermatitis and alopecia. 5. Nektar is developing additional products for cancer treatment.

5m saved
Insight
Article

FAQ

Why Neutral?

Current results announcement typically does not induce significant price changes. Historical patterns show stable stock movements during such financial disclosures.

How important is it?

Q2 results could indicate company performance but are speculative until disclosure. Ongoing trials may hold greater significance for future performance.

Why Short Term?

Immediate effects from Q2 results and call may influence stocks. However, long-term potential hinges on trial results and broader market conditions.

Related Companies

VRTXREGNABBV
, /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 7, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through September 7, 2025. To access the conference call by phone, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.  About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn. Contacts: For Investors: Corey Davis, Ph.D.LifeSci Advisors, LLC[email protected]  212-915-2577 Ahu Demir, Ph.D.LifeSci Advisors, LLC[email protected] 212-915-3820 For Media: Madelin HawtinLifeSci Communications603-714-2638[email protected] SOURCE Nektar Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News